New Drugs by unknown
ments find the clinic useful for special investigations on contact dermatitis, eczema,
and obscure nose and chest troubles, and it soon becomes a centre for research and
instruction.
Some of the research problems are too difficult for the unaided clinician, and they
will be solved only when clinician, pathologist, and physiologist effectively join
forces.
Lack of funds for research is obviously a major difficulty, but each year enormous
sums are spent on symptomatic and proprietary remedies for asthma, and it would
be good economy for the asthmatic individuals to divert some of their expenditure
into research. Perhaps it may be possible to organise them effectively so that
they can help more actively.
In conclusion, one might repeat that the lot of patients with severe, chronic
asthma is a hard one and that they are deserving of much more attention.
Pessimism which leads to inactivity and an attitude of laissez-faire is to be strongly
depreciated because, even with our imperfect knowledge, much can be done for
the majority of patients.
Progress in the future will be facilitated by the establishment of more special
asthma clinics, by well-planned research, and by the organisation and instruction
of the numerous asthma patients who could do much more to assist.
NEW DRUGS
THIAZAMIDE, which has recently been made generally available, was intro-
duced for clinical trial under its laboratory number "M&B 760." It resembles
Dagenan-M&B 693 in chemical and physical properties. The anti-pneumococcal
and anti-streptococcal activity of THIAZAMIDE is slightly lower than that of
"M&B 693," but in staphylococcal infections THIAZAMIDE is claimed to be the
rather more active of the two. It is also better tolerated than "M&B 693" and
provides an alternative chemo-therapeutic agent for use in gonococcal, menin-
gococcal, pneumococcal, and other infections.
A pamphlet gives details of the in vivo and in vitro activity of THIAZAMIDE
against a number of micro-organisms, and includes particulars of clinical indi-
cations, dosage, absorption, and excretion. Members of the medical profession
may obtain copies of this pamphlet on request to Pharmaceutical Specialities (May
& Baker) Ltd., Dagenham.
WE have just received a copy of the second edition of the pamphlet on OPACOL,
which has been sent to us by the makers, Pharmaceutical Specialities (May & Baker)
Limited, Dagenham.
OPACOL, a British preparation of sodium tetraiodophenolphthalein for oral
administration, now has an established place among the most reliable and most
widely used contrast media for X-ray visualisation of the gall-bladder.
The pamphlet contains detailed information on the properties, dosage and
administration of OPACOL, and copies will be sent gladly to members of the
medical profession on request to Pharmaceutical Specialities (May & Baker)
Limited, Dagenham.
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